Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.185 USD | -5.77% | -8.21% | +4.77% |
Apr. 04 | UBS Adjusts Kodiak Sciences Price Target to $5 From $3, Maintains Neutral Rating | MT |
Apr. 01 | Barclays Raises Price Target on Kodiak Sciences to $3 From $2, Maintains Underweight Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+4.77% | 167M | |
-2.26% | 103B | |
+1.41% | 95.71B | |
+0.93% | 22.02B | |
-17.84% | 20.9B | |
-9.68% | 17.85B | |
-42.83% | 16.21B | |
-17.63% | 15.52B | |
+4.55% | 13.86B | |
+32.11% | 12.04B |
- Stock Market
- Equities
- KOD Stock
- News Kodiak Sciences Inc.
- Kodiak Sciences Completes Enrollment for Phase 3 Trial of Eye Disease Drug Candidate KSI-301